Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 40Recurrence 9Neoplasms, Plasma Cell 7Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, B-Cell 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Epstein-Barr Virus Infections 1Disease Progression 1Disease 1Central Nervous System Neoplasms 1Amyloidosis 1

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × pomalidomide × Clear all
NCT03582033 2024-12-24

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Terminated
83 enrolled 57 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡